Endometrial Neoplasms

• 

  Subject Areas on Research

  • "You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer. 
  • A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. 
  • A balancing act: RNA binding protein HuR/TTP axis in endometriosis patients. 
  • A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. 
  • A diagnostically useful histopathologic feature of endometrial polyp: the long axis of endometrial glands arranged parallel to surface epithelium. 
  • A double-blind randomized study on the effects of red clover isoflavones on the endometrium. 
  • A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. 
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. 
  • A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. 
  • A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery. 
  • A primer of endometrial cytology with histological correlation. 
  • A remark about CYP1A1 Thr461Asn genotype frequencies in a recent endometrial cancer case-control study. 
  • Accuracy of endometrial thickness in detecting benign endometrial pathology in postmenopausal women. 
  • Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. 
  • Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. 
  • Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. 
  • Allelotype of endometrial carcinoma. 
  • Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer. 
  • Analgesic medication use and risk of epithelial ovarian cancer in African American women. 
  • Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study. 
  • Association between endometriosis and gynecological cancers: a critical review of the literature. 
  • Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. 
  • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 
  • Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. 
  • Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome. 
  • Benefits and drawbacks to hormone replacement therapy among nursing home patients. 
  • Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. 
  • Biomarkers in the endometrium. 
  • Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. 
  • Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning. 
  • CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. 
  • Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? 
  • Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. 
  • Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. 
  • Clinical and pathologic correlates in surgical stage II endometrial carcinoma. 
  • Common variants at 19p13 are associated with susceptibility to ovarian cancer. 
  • Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. 
  • Controversies in Sentinel Lymph Node Biopsy for Gynecologic Malignancies. 
  • Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. 
  • Cost effectiveness of a test to detect metastases for endometrial cancer. 
  • Cost-effectiveness analysis of annual screening strategies for endometrial cancer. 
  • Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer. 
  • Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. 
  • Cost-effectiveness of treatment of early stage endometrial cancer. 
  • Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. 
  • Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182. 
  • Current state of sentinel lymph nodes for women with endometrial cancer. 
  • Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. 
  • DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. 
  • Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions. 
  • Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution. 
  • Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. 
  • Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. 
  • Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results? 
  • Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. 
  • Discussion: 'Tumor diameter as a predictor in endometrial cancer surgery' by Yanazume et al. 
  • Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. 
  • Distress screening in endometrial cancer leads to disparity in referral to support services. 
  • Distribution of integrin cell adhesion molecules in endometrial cancer. 
  • Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? 
  • Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. 
  • Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors. 
  • Endometrial cancer. 
  • Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. 
  • Endometrial cancer: stage at diagnosis and associated factors in black and white patients. 
  • Endometrial carcinoma and its precursors. 
  • Endometrioid carcinoma of the endometrium with sertoliform differentiation. 
  • Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. 
  • Estimated Performance of Transvaginal Ultrasonography for Evaluation of Postmenopausal Bleeding in a Simulated Cohort of Black and White Women in the US. 
  • Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model. 
  • Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. 
  • Evaluation of pelvic washing specimens in patients with endometrial cancer: Cytomorphological features, diagnostic agreement, and pathologist experience. 
  • Evaluation of two management strategies for preoperative grade 1 endometrial cancer. 
  • Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. 
  • Extent of lymphadenectomy and postoperative major complications among women with endometrial cancer treated with minimally invasive surgery. 
  • Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. 
  • Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. 
  • Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. 
  • GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. 
  • GPR54 is a target for suppression of metastasis in endometrial cancer. 
  • Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability. 
  • Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. 
  • Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. 
  • Germline PTEN mutations as a cause of early-onset endometrial cancer. 
  • Goblet-cell mucinous epithelium lining the endometrium and endocervix: evidence of metastasis from an appendiceal primary tumor through the use of cytokeratin-7 and -20 immunostains. 
  • High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. 
  • Hormonal and Growth Regulation of Epithelial and Stromal Cells From the Normal and Malignant Endometrium by Pigment Epithelium-Derived Factor. 
  • Hormonal treatment of an endometrial stromal nodule followed by local excision. 
  • How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. 
  • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. 
  • Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. 
  • IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. 
  • Impact of age at diagnosis on racial disparities in endometrial cancer patients. 
  • Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. 
  • Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. 
  • Induction of cyclooxygenase-2 in human endometrial stromal cells by malignant endometrial epithelial cells: evidence for the involvement of extracellularly regulated kinases and CCAAT/enhancer binding proteins. 
  • Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. 
  • Integrated genomic characterization of endometrial carcinoma. 
  • Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients. 
  • Interval to treatment in endometrial cancer. 
  • Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis. 
  • Low-Volume Lymph Node Metastases in Endometrial Carcinoma. 
  • Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. 
  • Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. 
  • Menstrual cyclic change of metastin/GPR54 in endometrium. 
  • Metastatic malignant melanoma in an endometrial polyp. 
  • Metformin is associated with improved survival in endometrial cancer. 
  • Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies. 
  • MicroRNAs in endometrial cancers from black and white patients. 
  • Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. 
  • Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. 
  • Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. 
  • Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. 
  • Modulation of implantation-associated integrin expression but not uteroglobin by steroid hormones in an endometrial cell line. 
  • Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. 
  • Molecular basis of endometrial cancer. 
  • Molecular classification of endometrial cancer: entering an era of precision medicine. 
  • Molecular testing for endometrial cancer: An SGO clinical practice statement. 
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. 
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. 
  • Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. 
  • Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. 
  • Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. 
  • Mutations of the E-cadherin gene in human gynecologic cancers. 
  • Mutations of the Ki-ras oncogene in endometrial carcinoma. 
  • NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. 
  • Novel Therapies in Gynecologic Cancer. 
  • OVX1 as a marker for early stage endometrial carcinoma. 
  • Obesity and altered angiogenic-related gene expression in endometrial cancer. 
  • Obesity: Too big a problem to ignore. 
  • Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Oral contraceptive pills. Prevention of ovarian cancer and other benefits. 
  • Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. 
  • Oral contraceptive use and risk of cancer--response. 
  • Overexpression and mutation of p53 in endometrial carcinoma. 
  • Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. 
  • PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. 
  • PTEN/MMAC1 mutations in endometrial cancers. 
  • Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody. 
  • Patterns and trends in the cause of death for patients with endometrial cancer. 
  • Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer. 
  • Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. 
  • Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer. 
  • Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. 
  • Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 
  • Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. 
  • Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. 
  • Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. 
  • Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies. 
  • Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. 
  • Prenatal diethylstilbestrol exposure and cancer risk in women. 
  • Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. 
  • Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. 
  • Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. 
  • Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. 
  • Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. 
  • Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. 
  • Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. 
  • Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer. 
  • Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. 
  • Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. 
  • Racial differences in tumor grade among women with endometrial cancer. 
  • Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 
  • Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. 
  • Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future. 
  • Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. 
  • Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients. 
  • Relationship between race and interval to treatment in endometrial cancer. 
  • Relationship between tamoxifen use and high risk endometrial cancer histologic types. 
  • Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. 
  • Response to Dr Sabater. 
  • Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. 
  • Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. 
  • Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. 
  • Robotically assisted fluorescence-guided lymph node mapping with ICG for gynecologic malignancies: a feasibility study. 
  • Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. 
  • Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? 
  • STAT1 drives tumor progression in serous papillary endometrial cancer. 
  • Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. 
  • Sentinel Lymph Node Biopsy in Endometrial Cancer: a New Standard of Care? 
  • Sentinel Lymph Node Technique in Endometrial Cancer. 
  • Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? 
  • Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. 
  • Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. 
  • Sentinel-lymph-node mapping in endometrial cancer - Authors' reply. 
  • Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis. 
  • Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma. 
  • Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. 
  • Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). 
  • Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. 
  • Sonography of benign cystic teratoma of the ovary: pitfalls in diagnosis. 
  • Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. 
  • Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? 
  • Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries? 
  • T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. 
  • TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Tamoxifen in postmenopausal women a safety perspective. 
  • Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. 
  • Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. 
  • The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma: A Pooled Data Analysis. 
  • The ProMisE of uniform care for endometrial cancer patients. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. 
  • The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. 
  • The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer. 
  • The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. 
  • The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. 
  • The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. 
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. 
  • The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. 
  • The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. 
  • The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. 
  • Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Endometrial Cancer. 
  • Transcript expression in endometrial cancers from Black and White patients. 
  • Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. 
  • Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis. 
  • Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. 
  • Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B. 
  • Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. 
  • Uterine Neoplasms. Clinical Practice Guidelines in Oncology. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial. 
  • Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. 
  • Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. 
  • What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer? 
  • p53 overexpression in advanced-stage endometrial adenocarcinoma. 
  • p53lyn and p56lyn: a new signaling pathway in human endometrium and endometrial adenocarcinomas. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute